CGEM
Income statement / Annual
Last year (2023), Cullinan Oncology, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Cullinan Oncology, Inc.'s net income was -$153.16 M.
See Cullinan Oncology, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00
|
$0.00
|
$18.94 M
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$310,000.00 |
$93,000.00 |
$53,000.00 |
$62,000.00 |
$70,000.00 |
$43,000.00 |
| Gross Profit |
-$310,000.00 |
-$93,000.00 |
$18.89 M |
-$62,000.00 |
-$70,000.00 |
-$43,000.00 |
| Gross Profit Ratio |
0 |
0 |
1 |
0 |
0 |
0 |
| Research and Development
Expenses |
$148.16 M
|
$91.95 M
|
$57.75 M
|
$43.21 M
|
$16.79 M
|
$9.58 M
|
| General & Administrative
Expenses |
$42.49 M
|
$40.19 M
|
$29.15 M
|
$17.12 M
|
$5.48 M
|
$5.00 M
|
| Selling & Marketing
Expenses |
$42.14 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$42.49 M
|
$40.19 M
|
$29.15 M
|
$17.12 M
|
$5.48 M
|
$5.00 M
|
| Other Expenses |
$440,000.00 |
$57,000.00 |
-$8,000.00 |
-$11,000.00 |
-$4,000.00 |
$0.00 |
| Operating Expenses |
$191.09 M |
$132.14 M |
$86.90 M |
$60.34 M |
$22.27 M |
$14.59 M |
| Cost And Expenses |
$191.09 M |
$132.14 M |
$86.90 M |
$60.34 M |
$22.27 M |
$14.59 M |
| Interest Income |
$21.63 M |
$6.61 M |
$477,000.00 |
$888,000.00 |
$620,000.00 |
$397,000.00 |
| Interest Expense |
$0.00 |
-$562.35 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$310,000.00
|
$93,000.00
|
$53,000.00
|
$62,000.00
|
$70,000.00
|
$43,000.00
|
| EBITDA |
-$190.34 M
|
-$408.92 M
|
-$67.95 M
|
-$60.34 M
|
-$22.20 M
|
-$14.54 M
|
| EBITDA Ratio |
0 |
0 |
-3.59 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
-3.59
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$21.87 M
|
$6.67 M
|
$469,000.00
|
$877,000.00
|
$616,000.00
|
$397,000.00
|
| Income Before Tax |
-$169.22 M |
$151.32 M |
-$67.49 M |
-$59.46 M |
-$21.65 M |
-$14.19 M |
| Income Before Tax Ratio
|
0
|
0
|
-3.56
|
0
|
0
|
0
|
| Income Tax Expense |
$14.12 M |
$42.12 M |
-$2.45 M |
-$8.61 M |
-$1.62 M |
$397,000.00 |
| Net Income |
-$153.16 M |
$111.21 M |
-$65.04 M |
-$50.85 M |
-$20.04 M |
-$14.19 M |
| Net Income Ratio |
0 |
0 |
-3.43 |
0 |
0 |
0 |
| EPS |
-3.69 |
2.46 |
-1.47 |
-1.17 |
-0.46 |
-1.24 |
| EPS Diluted |
-3.69 |
2.38 |
-1.47 |
-1.17 |
-0.46 |
-1.24 |
| Weighted Average Shares
Out |
$41.51 M
|
$45.16 M
|
$44.29 M
|
$43.52 M
|
$43.52 M
|
$11.45 M
|
| Weighted Average Shares
Out Diluted |
$41.55 M
|
$46.64 M
|
$44.29 M
|
$43.52 M
|
$43.52 M
|
$11.45 M
|
| Link |
|
|
|
|
|
|
